Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Collagen type I alpha 1 chain (COL1A1) mRNA 3' untranslated region (3'UTR) is a critical regulatory segment of the transcript that encodes the primary component of type I collagen [1]. This region governs the stability and translational efficiency of the mRNA through interactions with various trans-acting factors, including the stabilizing poly(C)-binding protein (alpha-CP) and the destabilizing miR-29 family of microRNAs [1, 2]. In fibrotic diseases, dysregulation of these interactions leads to the pathological stabilization of COL1A1 mRNA, resulting in the excessive accumulation of collagen and subsequent organ scarring [3]. As a therapeutic target, the 3'UTR is addressed using microRNA mimics, such as Remlarsen, or antisense oligonucleotides designed to accelerate mRNA decay or block stabilizing factors [4]. Targeting this non-coding region offers a precise mechanism to modulate collagen production at the post-transcriptional level, providing a potential treatment for conditions like systemic sclerosis and pulmonary fibrosis [4, 5]. Research indicates that the 3'UTR contains specific C-rich elements that are essential for the high-level expression of collagen in activated fibroblasts [1]. By disrupting these regulatory motifs, it is possible to selectively reduce the synthesis of type I collagen without affecting the production of other essential cellular proteins [3, 4].
Regulation of mRNA degradation and translation efficiency through the recruitment of the RNA-induced silencing complex (RISC) or by blocking stabilizing protein-RNA interactions [1, 2, 4].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen type I alpha 1 chain mRNA 3' untranslated region (COL1A1 mRNA 3'UTR).